texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Ashley E. Ross, M.D., Ph.D.

General Summary

Dr. Ross specializes in urology and urologic oncology and is a nationally recognized expert in prostate cancer. Dr. Ross performs prostate cancer screening, prostate biopsy (including MRI-fusion biopsy), active surveillance, robotic prostatectomy, open radical prostatectomy, and salvage and primary cryoablation of the prostate. Prior to joining Texas Urology Specialists, Dr. Ross served as director of the Johns Hopkins Urology Prostate Cancer Program and as an associate professor in the Johns Hopkins School of Medicine departments of urology and oncology.

Education

  • Residency in Urology
    Chief Resident, Johns Hopkins Medical Institution, Baltimore, MD
  • Internship in Surgery
    Johns Hopkins Medical Institution, Baltimore, MD
  • Medical Doctorate
    Johns Hopkins University School of Medicine, Baltimore, MD
  • Doctor of Biochemistry, Cellular and Molecular Biology
    Johns Hopkins University School of Medicine, Baltimore, MD

Medical Practice

Other Information

Dr. Ross enjoys hiking, spending time with family and motorcycle riding.

Accolades & Memberships

  • Alpha Omega Alpha
  • American Urologic Association
  • American Society of Clinical Oncology
  • Prostate Cancer Foundation Young Investigator Award, 2015
  • Department of Defense Prostate Cancer Research Award, 2015
  • Patrick C. Walsh Research Award, 2015
  • Johns Hopkins Clinical Scientist Award, 2012

Community Service

Research Interest

Scholarly Leadership

Dr. Ross has published more than 90 peer reviewed articles related to prostate cancer. He currently is an associate editor of the journals Prostate Cancer and Prostatic Diseases, Urology, and the Annals of Surgical Oncology, and serves on the editorial board of the British Journal of Urology, and Urology Practice. He has been invited to moderate and speak at meetings of the American Urological Association, American Society of Radiation Oncologists, Society of Urological Oncology, National Comprehensive Cancer Network, and Prostate Cancer Foundation.

Publications

  • Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model

    Journal of Clinical Oncology, 2017

  • Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens

    European Urology, 2017

  • Genomic testing for localized prostate cancer: where do we go from here?

    Current Opinions in Urology, 2017

  • Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice

    Prostate Cancer Prostatic Diseases, 2017

  • Dynamic Contrast Enhanced MRI Improves Classification of Prostate Lesions: A Study of Pathologic Outcomes on Targeted Prostate Biopsy

    Journal of Urology, 2017

Show all Publications
  • PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study

    Journal of Urology, 2017

  • Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk

    Prostate Cancer Prostatic Diseases, 2016

  • Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential

    Journal of Urology , 2016

  • Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer:  a matched retrospective analysis

    Lancet Oncology, 2016

  • Multigene Testing in Localized Prostate Cancer

    Journal of the National Comprehensive Cancer Network, 2016

  • Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations

    Nature Reviews Urology, 2016